Grifols

As #IPAW2024 comes to an end, we would like to highlight how plasma-derived medicines are essential far beyond rare and chronic diseases. Hospitals and clinics use these treatments every day for various common and emergency situations, such as animal bites, burns, shock, trauma, rhesus (Rh) incompatibility during pregnancy, and more. In December 2023, the European Medicines Agency (EMA) recognized the vital importance of these medicines by listing almost all of them on the European Union’s first Critical Medicines List. Through Grifols’ Global Plasma Self-sufficiency Program, we are establishing paradigm-changing agreements around the world that support countries and regions in their efforts to ensure their patient populations have the plasma treatments they absolutely depend on. #PlasmaConnectsUs

We're excited to join the global community in celebrating World Mental Health Day. At Grifols, mental health is a priority, and we are dedicated to fostering a supportive and healthy work environment. As part of this commitment, we have implemented a comprehensive Mental Health Policy and a Wellbeing Plan, where mental health serves as a key pillar. We believe that supporting the mental well-being of our employees is not only essential for their personal and professional growth, but also vital to our overall success as a company. #WeAreGrifols #WorldMentalHealthDay #TogetherForMentalHealth

Continuing with the celebration of the #IPAW2024, we would like to highlight the uniqueness of plasma-derived medicines. Unlike other pharmaceuticals, the production of plasma-derived medicines starts with a biological material, human plasma. It can take up to 12 months from plasma donation to the patient receiving a plasma-derived medicine. This is due to the long, complex and highly regulated manufacturing process required to produce these high-quality medicines. Learn more on the importance of plasma 👉 http://spr.ly/6049UyF5t #PlasmaConnectsUs

⚽ It is an honor to sponsor, for the fourth year in a row, UEFA's women's football competitions. We firmly believe that sports are one of the most powerful platforms for promoting gender equality. Every female athlete dreaming big inspires other women and girls working to achieve extraordinary goals. As the UEFA Women's Champions League season 24/25 starts the group stage, sixteen teams are aiming to get to the final in Lisbon. We wish the best of luck to all players. Their ambition and strength pave the way for new opportunities for all. #GrifolsSocialImpact #UWCL

We are excited to kick off International Plasma Awareness Week #IPAW2024, a week dedicated to raising global awareness about plasma collection, recognizing the contributions of plasma donors and increasing understanding about plasma-derived medicines. Millions of people around the globe with rare and chronic diseases as well as others facing trauma and medical emergencies rely on plasma-derived medicine. The number of patients in need has risen in recent years. These medicines are only possible because of plasma donations. Donors’ generosity makes a world of difference. We want you to meet some of these incredible heroes. #PlasmaConnectsUs

We are excited to announce the launch of the first edition of the Strategy Program, a premier global initiative designed to enhance leadership expertise with a strategic approach. This 9-month program is set to shape the future of our organization by preparing individuals for key senior leadership roles.     In collaboration with Esade Business School, participants will engage in a rigorous curriculum that combines theoretical knowledge with practical application to build high-performing, inclusive teams, ensuring they are well-equipped to lead our organization into the future. This program underscores Grifols' commitment to nurturing talent and driving excellence at every level. #WeAreGrifols #LeadingTheFuture #businessstrategy

We are pleased to announce that GigaGen, a subsidiary of Grifols, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNTs) and a second biothreat of interest to the agency. The contract, worth up to $135.2M, will support the creation, manufacturing and initial clinical development of a drug product that targets the biothreats of both programs. For more information, see the press release 👉 http://spr.ly/6042Uruj8 #WeAreInnovation #biothreats

This year marks an incredible milestone for Grifols UK, as we celebrate 45 years of business in the UK. Starting in Thetford in October, 1979 as Alpha Therapeutic UK Ltd, and becoming Grifols UK Ltd in 1998, we have grown to become a trusted supplier of essential healthcare products and services. Today, with nearly 70 employees across our Biopharma and Diagnostics divisions, we’re proud to continue providing those products and services that improve patients' health and quality of life across Great Britain and Northern Ireland. We want to thank the talented individuals who have contributed to our success, as well as our strong partnerships with the UK healthcare system. 🎉 Here’s to many more years of success, innovation, and making a difference! #GrifolsUK #WeAreHealthcare

Our site in Dublin (Ireland) has become a key international center for manufacturing, logistics and global supply for our Biopharma business unit. Three years ago, we initiated a global transformation to optimize and improve supply chain operations to ensure a more efficient and collaborative process throughout the organization. We want you to meet Colum Meehan, he’s leading from Ireland the transformation of our End-to-End Supply Chain. His goal is to improve the agility of the company, to optimize the supply chain to easily adapt to market changes. #SupplyChain #GrifolsIreland #GrifolsTeam

During Global ITP Awareness Week, we join with the international community and ITP patient organizations around the world to promote public awareness of this rare autoimmune disease.     Affecting 10-62 people per 100,000 worldwide, Immune thrombocytopenia (ITP) is a blood disorder in which the immune system attacks and destroys the body's own blood platelets, which are essential for clotting blood.     At Grifols we foster research and innovation  in awareness, diagnosis and management of ITP through our GRAIT Awards Program to benefit patients everywhere.  To learn more, visit 👉 https://ow.ly/wTyC50POv2k     #autoimmunedisease #itpawareness #blooddisorder #WhatWeDoMatters